Helix Expands Operations at London
Elaborating on the HGPL plans, Mr. Mohan RK Nimmagadda, CEO and Director stated that HGPL is ambitious and will be improving its target base to eventually emerge as the global Bio-Computational CRO major and provide comprehensive and customized solutions to the industry.
The Director has also announced that, Dr. Rajani Kanth Vangala has joined formally as Director& Chief Scientific Officer (CSO) for Helix Genomics Private Limited, and will look after its London operations and will be involved in product development, contract research and consulting. Dr. Vangala was previously working at Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden.
Dr. Vangala has more than eight years of biological and bio-computational research experience and published in internationally acclaimed scientific journals. He has worked on subjects like Drosophila genetics, Proteomics and Genomics and has developed new computational algorithms for gene prediction, microarray/ proteomics data analysis.
Adding further the Director said HGPL will strengthen its marketing efforts by entering into multiple marketing alliances and collaborations across Europe. Additionally HGPL will focus on Software Licensing / Marketing and Contract Research activity and provide custom solutions in Europe.
HGPL technologies will be key drivers to faster and effective R&D initiatives and we offer custom designed solutions, products and services to the global Biotech/ Pharmaceutical industry and to academia, he added.
Topics
Organizations
Other news from the department business & finance
These products might interest you
Limsophy by AAC Infotray
Optimise your laboratory processes with Limsophy LIMS
Seamless integration and process optimisation in laboratory data management
ERP-Software GUS-OS Suite by GUS
Holistic ERP solution for companies in the process industry
Integrate all departments for seamless collaboration
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.